Roche Holding/Fr. ROP
1D1W1MYTD1Y5YMAX
Capital at risk
About Roche Holding
- Ticker
- Fr. ROP
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 103,249
- Headquarters
- Basel, Switzerland
- Website
- www.roche.com
Roche Holding Metrics
BasicAdvanced
CHF 290B
23.61
CHF 15.33
0.34
CHF 9.80
2.71%
Price and volume
Market cap
CHF 290B
Beta
0.34
52-week high
CHF 375.80
52-week low
CHF 291.00
Average daily volume
885K
Dividend rate
CHF 9.80
Financial strength
Current ratio
1.228
Quick ratio
0.8
Long term debt to equity
0.729
Total debt to equity
0.907
Dividend payout ratio (TTM)
61.50%
Interest coverage (TTM)
18.24%
Profitability
EBITDA (TTM)
23,964
Gross margin (TTM)
74.17%
Net profit margin (TTM)
19.60%
Operating margin (TTM)
33.12%
Effective tax rate (TTM)
18.74%
Revenue per employee (TTM)
CHF 610,000
Management effectiveness
Return on assets (TTM)
13.51%
Return on equity (TTM)
38.11%
Valuation
Price to earnings (TTM)
23.607
Price to revenue (TTM)
4.577
Price to book
8.86
Price to tangible book (TTM)
51.68
Price to free cash flow (TTM)
20.741
Free cash flow yield (TTM)
4.82%
Free cash flow per share (TTM)
17.454
Dividend yield (TTM)
2.71%
Forward dividend yield
2.71%
Growth
Revenue change (TTM)
-0.83%
Earnings per share change (TTM)
30.57%
3-year revenue growth (CAGR)
0.23%
10-year revenue growth (CAGR)
2.01%
3-year earnings per share growth (CAGR)
3.87%
10-year earnings per share growth (CAGR)
3.82%
3-year dividend per share growth (CAGR)
1.04%
10-year dividend per share growth (CAGR)
1.92%
Bulls say / Bears say
Underlying momentum is solid: first-half 2026 group sales increased 6% at constant exchange rates, core operating profit rose 10%, and Roche reaffirmed its mid-single-digit sales-growth and high-single-digit core-EPS outlook for 2026. (Roche)
The pipeline produced important catalysts, including positive Phase III fenebrutinib data in multiple sclerosis and five U.S. FDA Priority Reviews across breast cancer, thyroid eye disease, colon cancer and kidney-related autoimmune diseases. (Roche)
Currency translation remains a material earnings headwind: first-half 2026 sales rose 6% at constant exchange rates but fell 2% in CHF, while core EPS also declined 2% in CHF because of Swiss-franc appreciation. (Reuters)
Vabysmo execution is a near-term concern: Reuters reported weaker-than-expected U.S. sales of Roche’s key ophthalmology drug, contributing to the softer first-half reported performance. (Reuters)
Patent erosion and pricing pressure remain structural risks: products with expired patents declined 8% at constant exchange rates in the first half, while Diagnostics was hurt by healthcare pricing reforms in China. (Roche)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Upcoming events
No upcoming events
Funds containing Roche Holding
AllEURGBPUSD
Fund name | Fund size | Fr. ROP weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 17.42% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 17.42% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 16.31% |
iShares STOXX Europe 50€EXW3 | €141M | 6.78% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 3.75% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.